Approval brings in 10Billion Market Cap. Take it or leave it. With 11 Applications for Cancer's therapy or cure, its very cheap. Years ago a company named Genentech was a hope and prey until they got an approved Cancer drug in which Roche took them out for many, many billions. Exel is the only Company with this much Cancer trials simultaneously and with very promising results.
Just plain silly to compare EXEL to Genentech! By the way Genentech had Herceptin, Rituxan and Avastin franchises, enormous stockpiles of cash (as in many many billions) when Roche bought them.
The thing about trials is...you don't KNOW how they are going to turn out until the data is collected, "promising" doesn't mean spit.
The "proof will be in the pudding," I personally happen to think that the pudding will taste mighty fine indeed! (Well...here's hoping anyway) :)